• L-NMMA acetate in NO Pathway Assays

  2026-09-18

  L-NMMA acetate provides a practical loss-of-function control for testing whether nitric oxide signaling drives differentiation, viability, or disease-relevant phenotypes. This guide translates dental follicle-cell findings into reproducible assay workflows, concentration screens, controls, and troubleshooting strategies.

• Self-Adaptive Nanocarriers in Pancreatic Cancer

  2026-09-18

  The ACS Nano study developed DATCPT, a pH/reactive oxygen species-responsive nanocarrier designed to overcome circulation, tumor binding, extracellular-matrix penetration, and metastatic signaling barriers in orthotopic pancreatic cancer. Its sequential activation strategy links tumor acidity with ROS-driven matrix remodeling and camptothecin delivery, providing a useful framework for evaluating multifunctional nanomedicines.

• Vardenafil HCl Trihydrate in PDE5 Assays

  2026-09-17

  Vardenafil HCl Trihydrate supports a connected workflow from quantitative PDE5 inhibition assays to cGMP-dependent smooth muscle relaxation research. Its strong PDE5 potency, measurable PDE isoform selectivity, and compatibility with proteoform-aware studies make it useful for mechanism-first translational experiments.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-17

  A 2025 study found that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, and neuropilin-1 in an antibody-based assay. Its systematic peptide-truncation and tyrosine-modification strategy identifies sequence-dependent effects that warrant validation in cell-based infection and receptor-context models.

• CCK-8 Restores Morphine-Impaired Hippocampal LTP

  2026-09-16

  The reference study showed that CCK-8 restored morphine-impaired hippocampal long-term potentiation in rats and enhanced potentiation in saline-treated controls. Antagonist experiments identified the CCK2 receptor, rather than CCK1, as the principal mediator, providing a pharmacological link between a brain–gut peptide and opioid-related synaptic plasticity.

• (-)-Arctigenin MEK1 Inhibitor Workflow

  2026-09-16

  Use (-)-Arctigenin as a reversible pharmacology probe to dissect LPS–NF-κB and MEK1-linked signaling in macrophage–breast cancer models. This workflow pairs solvent discipline, time-resolved pathway measurements, and EV-miRNA assays so reduced invasion is not mistaken for nonspecific cytotoxicity.

• PLAC1 as a Target in Clear Cell Renal Cell Carcinoma

  2026-09-15

  This study integrates TCGA analysis, experimental validation, PLAC1 knockdown, and high-throughput virtual screening to identify PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma. Amaronol B and canagliflozin reduced PLAC1 expression and restrained ccRCC progression in the reported in vitro models, providing a starting point for target-oriented validation rather than a clinically established treatment.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-09-15

  Lutomski and colleagues developed a native mass spectrometry workflow that releases membrane proteins and signaling complexes directly from retina rod disc membranes, allowing proteoforms, post-translational modifications, and ligand interactions to be examined together. Their analysis shows why lipidation and other proteoform features can alter receptor assembly and off-target phosphodiesterase binding, with important implications for interpreting PDE5 inhibitor selectivity.

• Cholecystokinin Octapeptide Ammonium: Mechanisms

  2026-09-14

  Cholecystokinin octapeptide ammonium, also called CCK-8 ammonium, is a sulfated brain–gut peptide salt that activates CCK1R and CCK2R signaling. Evidence supports context-dependent effects on opioid-withdrawal anxiety, neuronal survival, immune signaling, and atrial natriuretic peptide secretion, but experimental dose, receptor subtype, sulfation state, and formulation must be controlled.

• VER 155008: HSP 70 Inhibitor Workflows

  2026-09-14

  Build a rigorous Hsp70 inhibition workflow around VER 155008, from ATPase target validation to apoptosis and cancer cell proliferation assays. The same perturbation strategy can also test how HSP70 activity shapes stress-induced protein condensates, while careful controls prevent solubility and interpretation errors.

• 2',7'-Dichlorofluorescein diacetate ROS Workflows

  2026-09-13

  Build more reproducible intracellular ROS measurement workflows with a cell-permeable fluorescent ROS probe designed for microscopy, flow cytometry, and plate assays. Learn how to translate ROS-responsive nanocarrier research into practical cancer-cell experiments while avoiding overinterpretation of a general oxidative-stress signal.

• Talin1–Piezo1–YAP Axis in Atherosclerosis

  2026-09-12

  A 2026 study identifies Talin1 as a mechanistic link between Piezo1-mediated calcium entry, YAP regulation, and inflammatory activation in endothelial cells. Using ApoE-knockout mice, disturbed-flow models, and human endothelial cultures, the work positions Talin1 as a potential target for studying inflammation-driven atherosclerosis.

• Isochlorogenic Acid A Hydrogel for Wound Repair

  2026-09-11

  A 2026 Gels study addressed the poor water solubility and stability of Isochlorogenic acid A by co-assembling it with Fe(III) into nanoparticles and embedding them in an amylopectin/carboxymethyl chitosan hydrogel. The resulting composite combined antibacterial activity, self-healing and adhesive behavior, cell-migration support, and improved wound closure with shifts in inflammatory and vascularization-associated markers.

• Silybin A: Mechanism-First Liver Cancer Research

  2026-09-11

  Silybin A provides a chemically defined way to study Silymarin-associated biology without confusing antioxidant effects with anti-invasive activity. This article translates ERK–MMP1 findings from a related phytochemical study into a rigorous, limitation-aware liver cancer assay strategy.

• Pam3CSK4 Workflows for TLR1/2 Immune Assays

  2026-09-10

  Build receptor-defined inflammation assays with Pam3CSK4 while separating direct immune activation from neural anti-inflammatory effects. This practical guide covers macrophage readouts, allergic airway inflammation model design, assay controls, and troubleshooting.

8605 records 1/574 page Next 12345 下5页 Last page